3.20
+0.25(+8.47%)
Currency In USD
Address
1200 Route 22 East
Bridgewater, NJ 08807
United States of America
Phone
908 955 3140
Website
Sector
Healthcare
Industry
Biotechnology
Employees
2
First IPO Date
January 12, 2022
| Name | Title | Pay | Year Born |
| Mr. Randy D. Milby MBA | President, Chief Executive Officer & Director | 830,369 | 1954 |
| Mr. Sireesh Appajosyula Pharm.D. | Chief Operating Officer & Director | 620,921 | 1976 |
| Mr. Vincent LoPriore | Executive Chairman of the Board | 0 | 1968 |
| Mr. Dong Kim | Chief Financial Officer | 0 | 1977 |
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.